- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Specificity constant.
Displaying page 1 of 1.
EudraCT Number: 2020-003323-42 | Sponsor Protocol Number: 29BRC20.0203 | Start Date*: 2021-03-01 | |||||||||||
Sponsor Name:CHRU de Brest | |||||||||||||
Full Title: Diagnostic Performance of prostate specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging for Pre-operative lymph Node assessment in intermediate and hig... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006038-37 | Sponsor Protocol Number: TAK-573-1501 | Start Date*: 2022-10-11 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refr... | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DE (Prematurely Ended) FR (Completed) IE (Completed) ES (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002169-14 | Sponsor Protocol Number: TAK-573-2001 | Start Date*: 2023-03-10 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With... | ||
Medical condition: Multiple Myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004547-35 | Sponsor Protocol Number: IMP27330.1 | Start Date*: 2007-01-10 | |||||||||||
Sponsor Name:Serono GmbH | |||||||||||||
Full Title: Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Moderate to severe chronic plaque psoriasis (PASI ≥ 12) failing to respond to, or with a contraindication to, or intolerant to other systemic therapies including cyclosporine, methotrexate and Psor... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000249-38 | Sponsor Protocol Number: R118439 | Start Date*: 2019-01-25 | |||||||||||
Sponsor Name:University of Manchester | |||||||||||||
Full Title: Phase II trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH | |||||||||||||
Medical condition: intracerebral haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
